INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 445m ago
HOUSE PTR44m ago
SEC 13F44m ago
ROBINHOOD CHAIN44m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Power Luke Thomas sold CAI

See Remarks · Caris Life Sciences, Inc. · Common Stock

Side
SELL
Value
$1.62M
Shares
60.9K
Price
$26.56
Executed
Dec 11, 2025
Disclosed
Dec 12, 2025
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Dec 11 executedDec 12, 2025 disclosed

CAI · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
22/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+18 / 25

    $1.6M reported value · 37.6% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · CAI

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    36
    DR
    Denton John RusselSee Remarks
    CAICaris Life Sciences, Inc.
    Open-market sale
    		SELL$239K
    7,500 sh
    		Sep 22, 2026Sep 23, 2026
    traded Sep 22, 2026
    		+1dSEC FORM 4

    Evidence

    55
    BJ
    Brille Brian JDirector, See Remarks
    CAICaris Life Sciences, Inc.
    Open-market sale
    		SELL$12.13M
    400.0K sh
    		Sep 17, 2026Sep 17, 2026
    traded Sep 17, 2026
    		+0dSEC FORM 4

    Evidence

    27
    BJ
    Brille Brian JDirector, See Remarks
    CAICaris Life Sciences, Inc.
    Option exercise
    		M$976K
    400.0K sh
    		Sep 17, 2026Sep 17, 2026
    traded Sep 17, 2026
    		+0dSEC FORM 4

    Evidence

    17
    BJ
    Brille Brian JDirector, See Remarks
    CAICaris Life Sciences, Inc.
    Option exercise
    		M—
    400.0K sh
    		Sep 17, 2026Sep 17, 2026
    traded Sep 17, 2026
    		+0dSEC FORM 4

    Evidence

    46
    SB
    Spetzler David BaxleyPresident
    CAICaris Life Sciences, Inc.
    Open-market sale
    		SELL$2.15M
    84.9K sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    19
    SB
    Spetzler David BaxleyPresident
    CAICaris Life Sciences, Inc.
    Option exercise
    		M$610K
    250.0K sh
    		Sep 4, 2026Sep 4, 2026
    traded Sep 4, 2026
    		+0dSEC FORM 4

    Evidence

    5
    SB
    Spetzler David BaxleyPresident
    CAICaris Life Sciences, Inc.
    Option exercise
    		M—
    250.0K sh
    		Sep 4, 2026Sep 4, 2026
    traded Sep 4, 2026
    		+0dSEC FORM 4

    Evidence

    50
    SB
    Spetzler David BaxleyPresident
    CAICaris Life Sciences, Inc.
    Open-market sale
    		SELL$9.73M
    393.1K sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    26
    SB
    Spetzler David BaxleyPresident
    CAICaris Life Sciences, Inc.
    Option exercise
    		M$2.44M
    1.00M sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    35
    SB
    Spetzler David BaxleyPresident
    CAICaris Life Sciences, Inc.
    Open-market sale
    		SELL$2.95M
    119.2K sh
    		Sep 4, 2026Sep 4, 2026
    traded Sep 4, 2026
    		+0dSEC FORM 4

    Evidence

    5
    SB
    Spetzler David BaxleyPresident
    CAICaris Life Sciences, Inc.
    Option exercise
    		M—
    1.00M sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    21
    FP
    Fredrickson David PaulDirector
    CAICaris Life Sciences, Inc.
    Grant or award
    		A—
    13.2K sh
    		Aug 14, 2026Aug 14, 2026
    traded Aug 14, 2026
    		+0dSEC FORM 4

    Evidence

    21
    GE
    Gilliam Joseph EDirector
    CAICaris Life Sciences, Inc.
    Grant or award
    		A—
    13.2K sh
    		Aug 14, 2026Aug 14, 2026
    traded Aug 14, 2026
    		+0dSEC FORM 4

    Evidence

    17
    VL
    Vacirca Jeff LDirector
    CAICaris Life Sciences, Inc.
    Grant or award
    		A—
    13.2K sh
    		Aug 14, 2026Aug 14, 2026
    traded Aug 14, 2026
    		+0dSEC FORM 4

    Evidence

    21
    ML
    Minor LloydDirector
    CAICaris Life Sciences, Inc.
    Grant or award
    		A—
    13.2K sh
    		Aug 14, 2026Aug 14, 2026
    traded Aug 14, 2026
    		+0dSEC FORM 4

    Evidence

    8
    DR
    Denton John RusselSee Remarks
    CAICaris Life Sciences, Inc.
    Tax withholding
    		F$92K
    6,047 sh
    		May 15, 2026May 18, 2026
    traded May 15, 2026
    		+3dSEC FORM 4

    Evidence

    8
    SB
    Spetzler David BaxleyPresident
    CAICaris Life Sciences, Inc.
    Tax withholding
    		F$211K
    13.9K sh
    		May 15, 2026May 18, 2026
    traded May 15, 2026
    		+3dSEC FORM 4

    Evidence

    16
    BJ
    Brille Brian JDirector, See Remarks
    CAICaris Life Sciences, Inc.
    Tax withholding
    		F$213K
    14.0K sh
    		May 15, 2026May 18, 2026
    traded May 15, 2026
    		+3dSEC FORM 4

    Evidence

    12
    PT
    Power Luke ThomasSee Remarks
    CAICaris Life Sciences, Inc.
    Tax withholding
    		F$149K
    9,771 sh
    		May 15, 2026May 18, 2026
    traded May 15, 2026
    		+3dSEC FORM 4

    Evidence

    9
    SB
    Spetzler David BaxleyPresident
    CAICaris Life Sciences, Inc.
    Grant or award
    		A—
    83.2K sh
    		Mar 6, 2026Mar 10, 2026
    traded Mar 6, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002072013-25-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 11, 2025
    Published
    Dec 12, 2025
    Ingested by INSIDER
    Nov 5, 04:28 UTC
    Last re-read
    Nov 5, 04:28 UTC

    Extracted facts

    Filer
    Power Luke Thomas
    Role
    See Remarks
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Caris Life Sciences, Inc.
    Ticker
    CAI
    Shares
    60.9K
    Price per share
    $26.56
    Value
    $1,616,444
    Execution date (reported)
    Dec 11, 2025
    Owned after transaction
    101.0K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 60.9K
    • Price: $26.5644

    = $1,616,444

    What this establishes

    Power Luke Thomas filed this Form 4 reporting a open-market sale of CAI on Dec 11, 2025. It became public on Dec 12, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    See Remarks
    Power Luke Thomascik:0002072013
    Issuer
    Caris Life Sciences, Inc.cik:0002019410

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.